Bristol-Myers Squibb Company (BMY) 72.22 $BMY
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), AGIO: 51.97 (+1.62), BMY: 72.22 (-0.43)
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:50AM CDT
Pfizer (PFE) announced final data from the phase III study on inotuzumab ozogamicin for the treatment of relapsed/refractory acute lymphoblastic leukemia.
ANIP: 53.19 (+1.14), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 80.01 (-0.40), ABBV: 59.93 (-1.07), LLY: 73.86 (-0.09), BMY: 72.22 (-0.43)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
New Data on Bristol-Myers Squibb's Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
BusinessWire - Fri Jun 10, 1:30AM CDT
--Among patients who responded to Opdivo, estimated median duration of remission was 7.8 months
BMY: 72.22 (-0.43)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 34.74 (-0.55), AMGN: 153.08 (-1.70), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Genocea Appoints Ron Cooper to Board of Directors
GlobeNewswire - Thu Jun 09, 3:30PM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron Cooper has joined its board of directors, effective immediately. Mr. Cooper currently serves as president and chief executive officer at Albireo Ltd.
GNCA: 3.86 (-0.08), BMY: 72.22 (-0.43)
Theravance Biopharma Signs Licensing Deal with Takeda
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:23AM CDT
Theravance Biopharma (TBPH) has entered into a global license, development and commercialization agreement with Takeda (TKPYY) for TD-8954.
PFE: 34.74 (-0.55), TBPH: 22.35 (-0.33), BMY: 72.22 (-0.43)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 116.79 (-0.22), RTRX: 17.19 (-0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
BusinessWire - Thu Jun 09, 9:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from investors and analysts.
BMY: 72.22 (-0.43)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association
BusinessWire - Thu Jun 09, 5:59AM CDT
--New analysis evaluating impact of time from diagnosis and prior lines of therapy in progression-free survival from Empliciti ELOQUENT-2 trial in relapsed or refractory multiple myeloma also to be presented
BMY: 72.22 (-0.43)
Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), TEVA: 53.22 (+0.21), BMY: 72.22 (-0.43)
Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)
BusinessWire - Wed Jun 08, 6:48AM CDT
--In this study, patients who tested positive via a common blood test for certain biomarkers of poor prognosis (anti-CCP or RF) were more likely to have a greater response with Orencia treatment than patients testing negative for the biomarkers
BMY: 72.22 (-0.43)
Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:34AM CDT
Pfizer (PFE) announced top-line results from the OPAL Beyond study on Xeljanz for the treatment of patients with active psoriatic arthritis.
ANIP: 53.19 (+1.14), PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), BMY: 72.22 (-0.43)
Bristol-Myers Squibb Announces Dividend
BusinessWire - Tue Jun 07, 3:15PM CDT
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2016, to stockholders of record at the close of business on July 1, 2016.
BMY: 72.22 (-0.43)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), RTRX: 17.19 (-0.21), BMY: 72.22 (-0.43)
Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 53.19 (+1.14), RTRX: 17.19 (-0.21), ALXN: 133.32 (-2.29), BMY: 72.22 (-0.43)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 80.01 (-0.40), LLY: 73.86 (-0.09), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 80.11 (-0.99), SRPT: 19.41 (-0.54), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), AGIO: 51.97 (+1.62), BMY: 72.22 (-0.43)
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:50AM CDT
Pfizer (PFE) announced final data from the phase III study on inotuzumab ozogamicin for the treatment of relapsed/refractory acute lymphoblastic leukemia.
ANIP: 53.19 (+1.14), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 80.01 (-0.40), ABBV: 59.93 (-1.07), LLY: 73.86 (-0.09), BMY: 72.22 (-0.43)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
New Data on Bristol-Myers Squibb's Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
BusinessWire - Fri Jun 10, 1:30AM CDT
--Among patients who responded to Opdivo, estimated median duration of remission was 7.8 months
BMY: 72.22 (-0.43)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 34.74 (-0.55), AMGN: 153.08 (-1.70), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Genocea Appoints Ron Cooper to Board of Directors
GlobeNewswire - Thu Jun 09, 3:30PM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron Cooper has joined its board of directors, effective immediately. Mr. Cooper currently serves as president and chief executive officer at Albireo Ltd.
GNCA: 3.86 (-0.08), BMY: 72.22 (-0.43)
Theravance Biopharma Signs Licensing Deal with Takeda
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:23AM CDT
Theravance Biopharma (TBPH) has entered into a global license, development and commercialization agreement with Takeda (TKPYY) for TD-8954.
PFE: 34.74 (-0.55), TBPH: 22.35 (-0.33), BMY: 72.22 (-0.43)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 116.79 (-0.22), RTRX: 17.19 (-0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
BusinessWire - Thu Jun 09, 9:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from investors and analysts.
BMY: 72.22 (-0.43)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association
BusinessWire - Thu Jun 09, 5:59AM CDT
--New analysis evaluating impact of time from diagnosis and prior lines of therapy in progression-free survival from Empliciti ELOQUENT-2 trial in relapsed or refractory multiple myeloma also to be presented
BMY: 72.22 (-0.43)
Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), TEVA: 53.22 (+0.21), BMY: 72.22 (-0.43)
Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)
BusinessWire - Wed Jun 08, 6:48AM CDT
--In this study, patients who tested positive via a common blood test for certain biomarkers of poor prognosis (anti-CCP or RF) were more likely to have a greater response with Orencia treatment than patients testing negative for the biomarkers
BMY: 72.22 (-0.43)
Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:34AM CDT
Pfizer (PFE) announced top-line results from the OPAL Beyond study on Xeljanz for the treatment of patients with active psoriatic arthritis.
ANIP: 53.19 (+1.14), PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), BMY: 72.22 (-0.43)
Bristol-Myers Squibb Announces Dividend
BusinessWire - Tue Jun 07, 3:15PM CDT
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2016, to stockholders of record at the close of business on July 1, 2016.
BMY: 72.22 (-0.43)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), RTRX: 17.19 (-0.21), BMY: 72.22 (-0.43)
Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 53.19 (+1.14), RTRX: 17.19 (-0.21), ALXN: 133.32 (-2.29), BMY: 72.22 (-0.43)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 80.01 (-0.40), LLY: 73.86 (-0.09), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 80.11 (-0.99), SRPT: 19.41 (-0.54), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
